R. Louis (Liège, Belgium), P. Rogliani (Roma (RM), Italy)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
I. Hoof (Hørsholm, Denmark), K. Bønnelykke (Copenhagen, Denmark), M. Witten (Hørsholm, Denmark), T. Stranzl (Hørsholm, Denmark), X. Li (Tucson, United States of America), D. Meyers (Tucson, United States of America), E. Bleecker (Tucson, United States of America), P. Andersen (Hørsholm, Denmark)
|    |
Effect of tezepelumab on exacerbation-related oral corticosteroid use in NAVIGATOR
A. Bourdin (Montpellier, France), A. Menzies-Gow (London, United Kingdom), G. Chupp (New Haven, CT, United States of America), C. Ambrose (Gaithersburg, MD, United States of America), K. Kmita (Warsaw, Poland), J. Llanos-Ackert (Thousand Oaks, CA, United States of America), G. Colice (Gaithersburg, MD, United States of America), B. Cook (Gaithersburg, MD, United States of America)
| |
Bronchial smooth muscle of severe asthmatic patients decreases rhinovirus replication within the epithelium through a CCL-20/PKR/eIF2-a dependent pathway
P. Esteves (PESSAC, France), B. Allard (PESSAC, France), A. Celle (PESSAC, France), I. Dupin (PESSAC, France), E. Maurat (PESSAC, France), O. Ousova (PESSAC, France), M. Thumerel (PESSAC, France), H. Begueret (PESSAC, France), T. Lassere (PESSAC, France), R. Marthan (PESSAC, France), P. Girodet (PESSAC, France), P. Berger (PESSAC, France), T. Trian (PESSAC, France)
| |
Effect of bronchial thermoplasty on histopathological parameters in distinct asthma endotypes/phenotypes
E. Papakonstantinou (Thessaloniki, Greece), T. Koletsa (Thessaloniki, Greece), L. Zhou (Basel, Switzerland), L. Fang (Basel, Switzerland), M. Roth (Basel, Switzerland), M. Karakioulaki (Basel, Switzerland), S. Savic (Basel, Switzerland), L. Grize (Basel, Switzerland), M. Tamm (Basel, Switzerland), D. Stolz (Basel, Switzerland)
| |
CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes
A. Papi (Ferrara, Italy), N. Barnes (Brentford, Middlesex & London, United Kingdom), A. Fowler (Brentford, Middlesex, United Kingdom), H. Kerstjens (Groningen, Netherlands), E. Kerwin (Medford, OR, United States of America), D. Mannino (Lexington, KY & Research Triangle Park, NC, United States of America), R. Nathan (Colorado Springs, CO, United States of America), I. Pavord (Oxford, United Kingdom), E. Pizzichini (Brentford, Middlesex & Santa Catarina, United Kingdom), D. Slade (Research Triangle Park, NC, United States of America), A. Zarankaite (Brentford, Middlesex, United Kingdom), J. Oppenheimer (Newark, NJ, United States of America)
| |
COVID-19 risk and outcomes in adult asthmatics treated with biologics or systemic corticosteroids: nationwide real-world evidence.
A. Yochai (Haifa, Israel), M. Humber (Paris, France), W. Saliba (Haifa, Israel)
| |
Evaluating contributions of mometasone (MF), indacaterol (IND) and glycopyrronium (GLY) to reduction of exacerbations in patients with inadequately controlled asthma: Results from the IRIDIUM study
K. Chapman (Toronto (ON), Canada), R. Van Zyl-Smit (Cape Town, South Africa), H. Kerstjens (Groningen, Netherlands), J. Maspero (Buenos Aires, Argentina), M. Hosoe (Basel, Switzerland), A. Tanase (Basel, Switzerland), A. Pethe (East Hanover, United States of America), P. D’Andrea (East Hanover, United States of America), D. Brittain (Basel, Switzerland)
| |
Efficacy of tezepelumab in adolescents with severe, uncontrolled asthma
E. Israel (Boston, United States of America), A. Menzies-Gow (London, United Kingdom), G. Chupp (New Haven, United States of America), C. Ambrose (Gaithersburg, United States of America), B. Cook (Gaithersburg, United States of America), G. Hunter (Cambridge, United Kingdom), J. Llanos-Ackert (Thousand Oaks, United States of America), J. Downie (Thousand Oaks, United States of America), G. Colice (Gaithersburg, United States of America)
| |
Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma
H. Heatley (Singapore, Singapore), T. Tran (Gaithersburg, United States of America), A. Bourdin (Montpellier, France), A. Menzies-Gow (London, United Kingdom), D. Jackson (London, United Kingdom), E. Maslova (Cambridge, United Kingdom), D. Skinner (Singapore, Singapore), V. Carter (Singapore, Singapore), D. Price (Singapore, Singapore)
| |
Late Breaking Abstract - Effects of tezepelumab on host epithelial tolerance to virus in patients with uncontrolled asthma
A. Sverrild (Copenhagen, Denmark), S. Cerps (Lund, Sweden), J. Nieto-Fontarigo (Lund, Sweden), S. Ramu (Lund, Sweden), M. Hvidtfeldt (Copenhagen, Denmark), J. Kearley (Gaithersburg, United States of America), J. Griffiths (Gaithersburg, United States of America), J. Parnes (Thousand Oaks, CA, United States of America), C. Porsbjerg (Copenhagen, Denmark), L. Uller (Lund, Sweden)
| |
Discussion
| |